Consensus Bausch Health Companies Inc.

Equities

BHC

CA0717341071

Market Closed - Nyse 04:00:01 2024-03-28 pm EDT 5-day change 1st Jan Change
10.61 USD +1.14% Intraday chart for Bausch Health Companies Inc. +11.68% +32.29%

Evolution of the average Target Price on Bausch Health Companies Inc.

Price target over the last 5 years

History of analyst recommendation changes

c8e60e380cdb6759264b21b91884e.vCK7aWtVdVk0Zjn4EkET9mel9x7L0jPCESSPqJkdo_A.9k7xDBwaJiFlMHuVeXVhmhXnoVGGmQCGImfAzfZR7rGEd_ogLh0TaUAWVg~f968ad02ad61d9250b73a80d4e2cd55a
RBC Lifts Price Target on Bausch Health to $9 From $8, Keeps Sector Perform Rating MT
North American Morning Briefing : Mood Lifted on Hopes Rate-Hike Cycle Has Peaked DJ
RBC Cuts Price Target on Bausch Health to $8 From $9 Ahead of Q3 Report, Keeps Sector Perform Rating MT
Fitch Affirms Bausch Health, Bausch Health America's Ratings; Bausch + Lomb's Rating Maintained MT
Jefferies Upgrades Bausch Health to Buy From Hold, Adjusts Price Target to $16 From $9 MT
Moody's Rates Bausch + Lomb's New Secured Debt Instruments MT
RBC Boosts Price Target on Bausch Health to $9 From $8 Ahead of Q2 Report, Maintains Sector Perform Rating MT
TD Cowen Downgrades Bausch Health to Market Perform From Outperform, Adjusts Price Target to $12 From $35 MT
Jefferies Adjusts Price Target on Bausch Health to $9.50 From $7, Maintains Hold Rating MT
RBC Cuts Price Target on Bausch Health to $8 From $9, Notes Concerns for Ability to Distribute Bausch + Lomb Shares, Keeps Sector Perform Rating MT
Factbox-US government to impose inflation penalties on 27 drugs RE
Bausch Health Price Target Raised to US$10 (From US$8), Market Perform Rating Maintained After "Solid Q4" and 2023 Guide MT
RBC Lifts Price Target on Bausch Health to $9 From $8, Maintains Sector Perform Rating MT
Fitch Lowers Bausch Health to RD; Upgrades to CCC Post Distressed Exchange; Also Downgrades Bausch + Lomb MT
Fitch Downgrades Bausch Health to 'RD'; Upgrades to 'CCC' Post Distressed Exchange AQ
Fitch Downgrades Bausch + Lomb's IDR to 'B-'; Evolving Rating Watch Pre and Post Downgrade AQ
S&P Upgrades Bausch Health, Affirms Rating on Bausch + Lomb MT
Piper Sandler Adjusts Bausch Health Cos.' Price Target to $6 from $7, Reiterates Neutral Rating MT
Fitch Downgrades Bausch Health, Bausch Health Americas; Rating Watch Negative Removed MT
RBC Capital Adjusts Bausch Health Price Target to $8 From $4.50, Maintains Sector Perform Rating MT
Fitch Downgrades Bausch Health Co's IDR to 'C' on Proposed Distressed Debt Exchange AQ
Fitch Maintains Evolving Ratings Watch on Bausch + Lomb's Ratings Watch AQ
Fitch Maintains Negative Rating Watch on Bausch Health, Maintains Bausch + Lomb on Rating Watch Evolving MT
Stifel Nicolaus Adjusts Price Target for Bausch Health Companies to $15 From $40, Maintains Buy Rating MT
BMO Capital Reviews Bausch Health's Q2 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
10.61 USD
Average target price
9.786 USD
Spread / Average Target
-7.77%
High Price Target
16 USD
Spread / Highest target
+50.80%
Low Price Target
7 USD
Spread / Lowest Target
-34.02%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Bausch Health Companies Inc.

RBC Capital Markets
Jefferies & Co.
TD Cowen
Piper Sandler
BMO Capital
Stifel Nicolaus
Truist Securities
JPMorgan Chase
Barclays
Spin-Off Research
BofA Securities
HC Wainwright
J.P. Morgan Chase
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
  1. Stock
  2. Equities
  3. Stock Bausch Health Companies Inc. - Nyse
  4. Consensus Bausch Health Companies Inc.